American Journal of Obstetrics & Gynecology
Volume 174, Issue 4 , Pages 1151-1160, April 1996

Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer☆☆☆★

Presented by invitation at the Fourteenth Annual Meeting of the American Gynecological and Obstetrical Society, Napa, California, September 7-9, 1995.

New York, New York, and Seattle, Washington

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ From the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,a and the Division of Oncology, Department of Medicine,b Albert Einstein College of Medicine, Bronx; the Department of Neoplastic Diseases, Mount Sinai Medical Center,c and the Division of Oncology, Department of Medicine, Kaplan Comprehensive Cancer Center, New York University Medical Center,d New York; and Immunex Corporation, Seattle.e

☆☆ Reprint requests: Carolyn D. Runowicz, MD, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, 1695 Eastchester Road, Suite 601, Bronx, NY 10461.

★ 0002-9378/96 $5.00 + 0 6/6/71412

PII: S0002-9378(96)70657-9

American Journal of Obstetrics & Gynecology
Volume 174, Issue 4 , Pages 1151-1160, April 1996

Article Tools

* Image Usage & Resolution